ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention

NCT07497594 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

1500

Enrollment

OTHER

Sponsor class

Conditions

Contact With or Exposure to Human Immunodeficiency Virus

Interventions

DRUG: Lenacapavir long-acting
DRUG: Tenofovi-Emtricitabine (TDF/FTC) tablet

Sponsor

Oswaldo Cruz Foundation